After adjusting for age, sex, type of regimen (FOLFOX or FOLFIRINOX), concomitant use of EGFR inhibitors, ICIs and bevacizumab, baseline arterial hypertension, ischemic heart disease, heart failure, chronic kidney disease, cerebrovascular disease, and epilepsy, the occurrence of early-onset toxicity yielded an HR of 1.61 [95% CI 1.44 to 1.80] in a multiple variable Cox proportional hazards model (p < 0.001). This evidence concerns the gene EGFR and cerebrovascular disorder.